These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 20359633)

  • 21. Treatment of higher-risk myelodysplastic syndrome.
    Garcia-Manero G
    Semin Oncol; 2011 Oct; 38(5):673-81. PubMed ID: 21943674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MDS: practical treatment approaches for physicians and nurses.
    Latsko JM; Stone R; Shadduck RK; Breed C; ;
    Clin Adv Hematol Oncol; 2005 Feb; 3(2):1-7. PubMed ID: 16173150
    [No Abstract]   [Full Text] [Related]  

  • 23. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
    Hackanson B; Robbel C; Wijermans P; Lübbert M
    Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm.
    Merkel DG; Nagler A
    Expert Rev Hematol; 2013 Dec; 6(6):665-76. PubMed ID: 24191866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents.
    Silverman LR
    Leuk Res; 2009 Dec; 33 Suppl 2():S18-21. PubMed ID: 20004792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.
    Pan F; Peng S; Fleurence R; Linnehan JE; Knopf K; Kim E
    Clin Ther; 2010 Dec; 32(14):2444-56. PubMed ID: 21353113
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?
    Lowder JN; Taverna P; Issa JP
    Epigenomics; 2015 Oct; 7(7):1083-8. PubMed ID: 26541345
    [No Abstract]   [Full Text] [Related]  

  • 28. Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes.
    Cogle CR; Imanirad I; Wiggins LE; Hsu J; Brown R; Scornik JC; Wingard JR
    Clin Adv Hematol Oncol; 2010 Jan; 8(1):40-6. PubMed ID: 20351682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New agents in myelodysplastic syndromes.
    Jabbour EJ; Giles FJ
    Curr Hematol Rep; 2005 May; 4(3):191-9. PubMed ID: 15865871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical experience with decitabine in North American patients with myelodysplastic syndrome.
    Yee KW; Jabbour E; Kantarjian HM; Giles FJ
    Ann Hematol; 2005 Dec; 84 Suppl 1():18-24. PubMed ID: 16273408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DNA methyltransferases as targets for cancer therapy.
    Ghoshal K; Bai S
    Drugs Today (Barc); 2007 Jun; 43(6):395-422. PubMed ID: 17612710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 5-Azacytidine/Azacitidine.
    Müller A; Florek M
    Recent Results Cancer Res; 2010; 184():159-70. PubMed ID: 20072837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current status of epigenetic treatment in myelodysplastic syndromes.
    Kuendgen A; Lübbert M
    Ann Hematol; 2008 Aug; 87(8):601-11. PubMed ID: 18392623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myelodysplasia: the good, the fair and the ugly.
    Schiffer CA
    Best Pract Res Clin Haematol; 2007 Mar; 20(1):49-55. PubMed ID: 17336254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epigenetic therapies move into new territory, but how exactly do they work?
    Tuma RS
    J Natl Cancer Inst; 2009 Oct; 101(19):1300-1. PubMed ID: 19755677
    [No Abstract]   [Full Text] [Related]  

  • 36. Immunological effects of hypomethylating agents.
    Lindblad KE; Goswami M; Hourigan CS; Oetjen KA
    Expert Rev Hematol; 2017 Aug; 10(8):745-752. PubMed ID: 28644756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.
    Kaminskas E; Farrell AT; Wang YC; Sridhara R; Pazdur R
    Oncologist; 2005 Mar; 10(3):176-82. PubMed ID: 15793220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decitabine in the treatment of myelodysplastic syndromes.
    Santos FP; Kantarjian H; Garcia-Manero G; Issa JP; Ravandi F
    Expert Rev Anticancer Ther; 2010 Jan; 10(1):9-22. PubMed ID: 20014881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group.
    Götze K; Platzbecker U; Giagounidis A; Haase D; Lübbert M; Aul C; Ganser A; Germing U; Hofmann WK
    Ann Hematol; 2010 Sep; 89(9):841-50. PubMed ID: 20567826
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hematologic outcomes of myelodysplastic syndromes treatment with hypomethylating agents in community practice.
    Bordoni RE; Feinberg BA; Gilmore JW; Haislip S; Jackson JH; Farrelly E; Kim E; Buchner D
    Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):350-4. PubMed ID: 21816373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.